Current updates in the medical management of obesity.
Khan A, Raza S, Khan Y, Aksoy T, Khan M, Weinberger Y, Goldman J.
Recent Pat Endocr Metab Immune Drug Discov · review; journal article · DOI 10.2174/187221412800604644 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för lorcaserin hydrochloride hemihydrate. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
26 träffarRandomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
O'Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, Raether B, Anderson CM, Shanahan WR.
Obesity (Silver Spring) · randomized controlled trial; journal article · DOI 10.1038/oby.2012.66Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist.
Usmani KA, Chen WG, Sadeque AJ.
Drug Metab Dispos · journal article · DOI 10.1124/dmd.111.0434145-HT(2C) receptor agonists and the control of appetite.
Halford JC, Harrold JA.
Handb Exp Pharmacol · review; journal article · DOI 10.1007/978-3-642-24716-3_16The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control.
Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ.
Neuropsychopharmacology · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/npp.2011.303Serotonergic anti-obesity agents: past experience and future prospects.
Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA.
Drugs · review; journal article · DOI 10.2165/11596680-000000000-00000Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM, Berlie HD.
Am J Health Syst Pharm · review; journal article · DOI 10.2146/ajhp100638A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, Anderson CM, BLOSSOM Clinical Trial Group.
J Clin Endocrinol Metab · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1210/jc.2011-1256Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.
Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, Rose JE.
J Pharmacol Exp Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/jpet.111.183525Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
Shram MJ, Schoedel KA, Bartlett C, Shazer RL, Anderson CM, Sellers EM.
Clin Pharmacol Ther · controlled clinical trial; comparative study; randomized controlled trial; journal article · DOI 10.1038/clpt.2011.20Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
Bays HE.
Expert Rev Cardiovasc Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1586/erc.10.22Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
Martin CK, Redman LM, Zhang J, Sanchez M, Anderson CM, Smith SR, Ravussin E.
J Clin Endocrinol Metab · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1210/jc.2010-1848The use of lorcaserin in the management of obesity: a critical appraisal.
Bai B, Wang Y.
Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s11945Lorcaserin--not a new weapon in the battle with appetite.
Halford JC.
Nat Rev Endocrinol · evaluation study; journal article · DOI 10.1038/nrendo.2010.193Trial of lorcaserin for weight management.
Floyd JS, Heckbert SR.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1009975Trial of lorcaserin for weight management.
Jia J, Xiong L, Chen S.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1009975Trial of lorcaserin for weight management.
von Haehling S.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1009975Lorcaserin for the treatment of obesity.
Redman LM, Ravussin E.
Drugs Today (Barc) · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1358/dot.2010.46.12.1556433[Lorcaserin for weight reduction for overweight and adipose adults].
Spaar A.
Praxis (Bern 1994) · comment; journal article · DOI 10.1024/1661-8157/a000313ACS chemical neuroscience molecule spotlight on Lorcaserin.
Hopkins CR.
ACS Chem Neurosci · editorial; review; journal article · DOI 10.1021/cn100059u[Recent progress and novel perspectives on obesity pharmacotherapy].
Faria AM, Mancini MC, Melo ME, Cercato C, Halpern A.
Arq Bras Endocrinol Metabol · review; journal article; english abstract · DOI 10.1590/s0004-27302010000600003Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group.
N Engl J Med · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa0909809Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
Bays HE.
Expert Rev Cardiovasc Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1586/erc.09.123Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, APD356-004 Study Group.
Obesity (Silver Spring) · randomized controlled trial; journal article · DOI 10.1038/oby.2008.537Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.
Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.107.133348Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA, Chen RR, Park DM, Prieto EB, Gallardo CS, Sengupta D, Dosa PI, Covel JA, Ren A, Webb RR, Beeley NR, Martin M, Morgan M, Espitia S, Saldana HR, Bjenning C, Whelan KT, Grottick AJ, Menzaghi F, Thomsen WJ.
J Med Chem · journal article · DOI 10.1021/jm0709034